DHT promotes hairgrowth in certain areas but causes scalp hair loss, highlighting a frustrating irony. Minoxidil is mentioned as a treatment that grows hair everywhere, including the scalp.
BPC-157 may promote hairgrowth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.
Topical sodium valproate may promote hairgrowth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.
The user experienced improved hairgrowth using Minoxidil twice daily, finasteride 1.25mg once daily, weekly dermarolling, supplements, and occasional ketoconazole shampoo for 5.5 months, but noticed hair shedding again after switching types of Minoxidil. Despite returning to the original Minoxidil, the user's hair condition worsened and shedding continued.
Andreas Townsend's hairgrowth, likely due to a combination of finasteride and minoxidil treatments, as well as possibly a hair transplant. People have been discussing the efficacy of these treatments in achieving Townsend's level of hairgrowth.
The user experienced significant hairgrowth using minoxidil 5%, finasteride 0.1% topical, dermarolling, and Nizoral shampoo, with only dry scalp as a side effect. They noted improved results after increasing the finasteride concentration.
ET-02 showed significant hairgrowth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
Stemoxydine's effects on hairgrowth are uncertain and not well-studied, with users reporting mixed results and concerns about maintaining gains. Some users combine it with 5AR inhibitors like Dutasteride, but results vary, and conditions like lichen planopilaris complicate treatment.
PP405 shows potential for hairgrowth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.
Clascoterone (Breezula) shows promising hairgrowth results, but skepticism remains due to past disappointments with new treatments. It may be a good alternative for those who can't tolerate finasteride or dutasteride, and can potentially be combined with them and minoxidil for better results.
DHT promotes beard growth but causes scalp hair loss due to inflammation and fibrosis. Treatments like finasteride and minoxidil help with hormonal signals and blood flow but don't address underlying inflammation.
PP405 shows some hairgrowth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.
Scalp massages may improve hairgrowth, with noticeable results in a few months. The technique involves detaching the skin from the skull, similar to detumescence therapy, and may be combined with other treatments for better results.
Minoxidil helps hairgrowth by increasing blood flow and prolonging the growth phase, but it doesn't address the root cause of hair loss, such as DHT sensitivity. Finasteride can help maintain some gains by blocking DHT, but stopping Minoxidil often leads to hair loss because the new hairs are dependent on it.
The user experienced significant hairgrowth after using minoxidil 5% and finasteride 1.25mg daily for three months, despite initial shedding. They noted improved hair density, especially at the temples, and plan to manage excess hairgrowth on the forehead.
KX-826 initially improves hairgrowth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
GT20029 showed significant hairgrowth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Minoxidil helps hairgrowth on both scalp and face, but stopping it leads to hair loss on the scalp, not the face. The user questions why scalp hair can't be maintained with finasteride or androgen blockers after stopping minoxidil, despite these treatments reducing DHT damage.
User experienced hairgrowth after 6 months using microneedling, minoxidil, ketoconazole, and biotin. Commenters suggest adding finasteride to treatment for better results and preventing further hair loss.
Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hairgrowth. A scalp biopsy is recommended to check for autoimmune-related hair loss.
Minoxidil can stimulate hairgrowth but does not prevent long-term hair loss, while finasteride or dutasteride is necessary to address DHT and maintain hair. Family hair history may not predict individual outcomes, and combining treatments like microneedling can enhance results.
The user reported significant hairgrowth after 8 months using a topical solution of 0.25% Finasteride and 8% Minoxidil, with no side effects. They also performed micro-needling and took multivitamins.
Microneedling can promote hairgrowth, but there is uncertainty about the best practices, including needle length, device, and session frequency. Users discuss using needle lengths between 0.5mm and 1.5mm, with some experiencing pinpoint bleeding, and emphasize the need for more reliable resources and guidelines.
The conversation discusses a user's hairgrowth routine involving scalp massages, dermastamping, and rosemary oil, with mixed opinions on its effectiveness. Some users suggest proven treatments like minoxidil and finasteride, while others debate the merits of alternative methods.
TDM-105795 is a potential hairgrowth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
A 32-year-old is seeing new hairgrowth after two months of using minoxidil foam twice daily, finasteride every other day, and weekly microneedling. They previously had a hair transplant but did not use medication afterward, which they now regret.
Breezula offers modest hairgrowth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.
Breezula shows promising hairgrowth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.